Search our site
Search our site

Professor Helmout Modjtahedi

Professor of Cancer Biology

About

After receiving my degree in Medical Laboratory Science from University of Ulster in 1989, I completed my PhD in Tumour Immunology at the Institute of Cancer Research/University of London in 1993. Subsequently, I worked as a Postdoctoral Research Fellow at the Institute of Cancer Research/University of London (1993-1999) and was appointed to a Clinical Lectureship in Pharmaco-Immunology/Tumour Immunology at the European Institute of Health and Medical Sciences/Postgraduate Medical School at the University of Surrey (1999-2007). I moved to the School of Life Sciences at Kingston University as Senior Lecturer in 2001, and became Reader in 2007. In 2012, I was promoted to Professor of Cancer Biology. I currently teach on a range of undergraduate and postgraduate bioscience programmes with particular focus on cancer related subjects and lead an active research group. In my laboratory, we particularly focus on cancer biology, therapeutics and diagnostics.

Areas of specialism

  • Cancer biology
  • Cancer therapeutics
  • Cancer diagnostics
  • Tumour biomarkers
  • Targeted therapy with monoclonal antibodies and small molecule tyrosine kinase inhibitors

Qualifications

  • Certificate
  • PhD, Tumour Immunology, Institute of Cancer Research, University of London
  • First Class BSc Honours in Medical Laboratory Science, University of Ulster

Professional membership

Member of American Association for Cancer Research

Member of British Association for Cancer Research

Fellow of the Institute of Biomedical Sciences (FIBMS)

Fellow of the Higher Education Academy (UK)

Research

My research expertise is translational cancer research. My research activities to date focus upon four key areas:

1) Studying the biological and clinical significance and targeting of growth factor receptors with tyrosine kinase activities in human cancers and other pathological conditions.

2) Development of monoclonal antibody (mAb)-based products for use in cancer diagnosis and therapy.

3) Predictive biomarkers for poor response to therapy with monoclonal antibodies and/or small molecule tyrosine kinase inhibitors in cancer.

4) Discovery of over expressed tumour antigens using monoclonal antibody-based technology.

Publications

Number of items: 27.

Article

Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles and Bahr, Georges (2017) Immunomodulatory effects of heat killed 'Mycobacterium obuense' on human blood dendritic cells. Innate Immunity, ISSN (print) 1753-4259 (Epub Ahead of Print)

Ioannou, Nikolaos, Seddon, Alan, Dalgleish, Angus, Mackintosh, David, Solca, Flavio and Modjtahedi, Helmout (2016) Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal Of Oncology, 48(3), pp. 908-918. ISSN (print) 1019-6439

Puvanenthiran, Soozana, Essapen, Sharadah, Seddon, Alan and Modjtahedi, Helmout (2016) Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of the HER inhibitors and cytotoxic drugs. International Journal Of Oncology, 49(5), pp. 1825-1838. ISSN (print) 1019-6439

Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2016) The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget, 8(5), pp. 7666-7677. ISSN (online) 1949-2553

Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2015) Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. British Journal of Cancer, 113(7), pp. 1010-1019. ISSN (print) 0007-0920

Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Akle, Charles and Bahr, Georges M (2015) Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model. Immunobiology, 220(12), pp. 1293-1304. ISSN (print) 0171-2985

Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout (2014) Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PloS one, 9(3), e91139. ISSN (print) 1932-6203

Navari, Mohsen, Zare, Mehrak, Javanmardi, Masoud, Asadi-Ghalehni, Majid, Modjtahedi, Helmout and Rasaee, Mohammad Javed (2014) Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope. Immunopharmacology and Immunotoxicology, 36(5), pp. 309-315. ISSN (print) 0892-3973

Modjtahedi, Helmout and Eccles, Suzanne (2014) GA201: a novel humanized and glycoengineered anti-EGFR antibody. Clinical Cancer Research, 20(4), pp. 1053-1054. ISSN (print) 1078-0432

Modjtahedi, Helmout, Cho, Byoung Chul, Michel, Martin C and Solca, Flavio (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's archives of pharmacology, ISSN (print) 0028-1298

Modjtahedi, Helmout, Ioannou, Nikolaos, Dalgleish, Angus, Mackintosh, David and Seddon, Alan M. (2013) Co-targeting of HER family members and IGF-IR in pancreatic cancer. International Journal Of Molecular Medicine, 32, S40-S40. ISSN (print) 1107-3756

Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan Michael and Modjtahedi, Helmout (2013) Prognostic significance and targeting of HER family in colorectal cancer. Frontiers in Bioscience, 18(2), pp. 394-421. ISSN (print) 1093-9946

Polycarpou, Elena, Meira, Lisiane B, Carrington, Simon, Tyrrell, Elizabeth, Modjtahedi, Helmout and Carew, Mark A (2013) Resveratrol 3-O-d-glucuronide and resveratrol 4'-O-d-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Molecular Nutrition and Food Research, 57(10), pp. 1708-1717. ISSN (print) 1613-4125

Ioannou, Nikolaos, Seddon, Alan M., Dalgleish, Angus, Mackintosh, David and Modjtahedi, Helmout (2013) Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer, 13(41), ISSN (print) 1471-2407

Ioannou, N., Seddon, A.M., Dalgleish, A., Mackintosh, D. and Modjtahedi, H. (2012) Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Frontiers in Bioscience, 17(1), pp. 2698-2724. ISSN (print) 1093-9946

Modjtahedi, H., Khelwatty, S.A., Kirk, R.S., Seddon, A.M., Essapen, S., Del Vecchio, C.A., Wong, A.J. and Eccles, S. (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer, 106, pp. 883-888. ISSN (print) 0007-0920

Modjtahedi, Helmout, Ali, Sumaira and Essapen, Sharadah (2012) Therapeutic application of monoclonal antibodies in cancer: advances and challenges. British Medical Bulletin, 104(1), pp. 41-59. ISSN (print) 0007-1420

Ioannou, N, Dalgleish, A G, Seddon, A M, Mackintosh, D, Guertler, U, Solca, F and Modjtahedi, H (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer, 105(10), pp. 1554-1562. ISSN (print) 0007-0920

Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M. and Modjtahedi, Helmout (2011) Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. International Journal of Oncology, 39(2), pp. 483-491. ISSN (print) 1019-6439

Shafi, Shahida, Lamb, David, Modjtahedi, Helmout and Ferns, Gordon (2010) Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit. International Journal Of Experimental Pathology, 91(3), pp. 224-234. ISSN (print) 0959-9673

Modjtahedi, Helmout and Essapen, Sharadah (2009) Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anti-Cancer Drugs, 20(10), pp. 851-855. ISSN (print) 0959-4973

Cunningham, Matthew P., Thomas, Hilary, Marks, Christopher, Green, Margaret, Fan, Zhen and Modjtahedi, Helmout (2008) Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. International Journal of Oncology, 33(5), pp. 1107-1113. ISSN (print) 1019-6439

Cunningham, Matthew P., Thomas, Hilary, Fan, Zhen and Modjtahedi, Helmout (2006) Responses of human colorectal tumor cells to treatment with the anti–epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Research, 66(15), pp. 7708-7715. ISSN (print) 0008-5472

Cunningham, Matthew P., Essapen, Sharadah, Thomas, Hilary, Green, Margaret, Lovell, David P., Topham, Clare, Marks, Christopher and Modjtahedi, Helmout (2005) Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. International Journal of Oncology, 27(2), pp. 317-325. ISSN (print) 1019-6439

Essapen, Sharadah, Thomas, Hilary, Green, Margaret, De Vries, Corrine, Cook, Martin G., Marks, Christopher, Topham, Clare and Modjtahedi, Helmout (2004) The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathalogical parameters. International Journal of Oncology, 24(2), pp. 241-248. ISSN (print) 1019-6439

Modjtahedi, Helmout, Moscatello, David K., Box, Gary, Green, Margaret, Shotton, Christine, Lamb, David J., Reynolds, Lesley J., Wong, Albert J., Dean, Christopher, Thomas, Hilary and Eccles, Suzanne (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti EGFR MAb ICR62: A two-pronged attack for tumour therapy. International Journal of Cancer, 105(2), pp. 273-280. ISSN (print) 0020-7136

Conference or Workshop Item

Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout (2013) Acquired resistance to anti-EGFR mAb ICR62 or afatinib is accompanied by upregulation of the EGFR in colorectal cancer. In: 104th Annual Meeting of the American Association for Cancer Research; 6-10 Apr 2013, Washington, U.S.A..

This list was generated on Tue Oct 24 04:48:27 2017 BST.
>

Looking for academic staff in the Faculty of Health, Social Care and Education? Visit the Faculty website

Site menu